6533b859fe1ef96bd12b7858

RESEARCH PRODUCT

Multiproject–multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy

Salvador TortajadaGeert PostmaÀNgel Moreno-torresAna Paula CandiotaLutgarde M. C. BuydensDaniel MonleonMargarida Julià-sapéJesús PujolElies Fuster-garciaSabine Van HuffelJohan A. K. SuykensBernardo CeldaJuan M. García-gómezCarles ArúsWillem J. MelssenP.w.t. KrooshofJan LutsJavier Vicente RobledoIván OlierM. Carmen Martínez-bisbalMontserrat Robles

subject

Multicenter evaluation studyDecision support systemComputer scienceBiophysicsBrain tumorDecision support systemsMachine learningcomputer.software_genreSensitivity and SpecificityBrain tumorsHealth informaticsAnalytical ChemistryPattern Recognition AutomatedArtificial IntelligenceMagnetic resonance spectroscopyBiomarkers TumorCIENCIAS DE LA COMPUTACION E INTELIGENCIA ARTIFICIALmedicineHumansRadiology Nuclear Medicine and imagingDiagnosis Computer-AssistedRadiological and Ultrasound TechnologyBrain Neoplasmsbusiness.industryReproducibility of ResultsPattern classificationmedicine.diseaseR1EuropeRadiology Nuclear Medicine and imagingFISICA APLICADAArtificial intelligencebusinesscomputerAlgorithmsResearch Article

description

[EN] Automatic brain tumor classification by MRS has been under development for more than a decade. Nonetheless, to our knowledge, there are no published evaluations of predictive models with unseen cases that are subsequently acquired in different centers. The multicenter eTUMOUR project (2004-2009), which builds upon previous expertise from the INTERPRET project (2000-2002) has allowed such an evaluation to take place. A total of 253 pairwise classifiers for glioblastoma, meningioma, metastasis, and low-grade glial diagnosis were inferred based on 211 SV short TE INTERPRET MR spectra obtained at 1.5 T (PRESS or STEAM, 20-32 ms) and automatically pre-processed. Afterwards, the classifiers were tested with 97 spectra, which were subsequently compiled during eTUMOUR. In our results based on subsequently acquired spectra, accuracies of around 90% were achieved for most of the pairwise discrimination problems. The exception was for the glioblastoma versus metastasis discrimination, which was below 78%. A more clear definition of metastases may be obtained by other approaches, such as MRSI + MRI. The prediction of the tumor type of in-vivo MRS is possible using classifiers developed from previously acquired data, in different hospitals with different instrumentation under the same acquisition protocols. This methodology may find application for assisting in the diagnosis of new brain tumor cases and for the quality control of multicenter MRS databases.

10.1007/s10334-008-0146-yhttps://doi.org/10.1007/s10334-008-0146-y